Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
Emerging Business Models in the Pharmaceutical Industries ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
The Increase <strong>in</strong> Revenues of<br />
<strong>the</strong> Big Pharmas Cont<strong>in</strong>ues<br />
The major driver towards<br />
<strong>in</strong>crease <strong>in</strong> revenues has been<br />
<strong>the</strong> broad product portfolio of<br />
fast grow<strong>in</strong>g, high value<br />
products.<br />
Benchmark<strong>in</strong>g - by Percentage Growth <strong>in</strong> Revenues<br />
Pfizer has booked <strong>the</strong> highest<br />
growth <strong>in</strong> revenues for <strong>the</strong> year<br />
2003 largely due to <strong>the</strong><br />
<strong>in</strong>clusion of Pharmacia<br />
products.<br />
All <strong>the</strong> companies except for<br />
Aventis have <strong>in</strong>creased<br />
revenues between 8% to 38%.<br />
The average <strong>in</strong>crease <strong>in</strong><br />
revenues is 10%.<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
-10<br />
-20<br />
Percentage Growth <strong>in</strong> Revenues of Big Pharmas<br />
Source: JSB Intelligence<br />
Pfizer<br />
Novatis<br />
BMS<br />
Strategic Analysis of <strong>the</strong> Pharma Market, Future Revenue <strong>Models</strong> and Key Players 51<br />
J&J<br />
Eli Lilly<br />
Wyeth<br />
Astra Zeneca<br />
Merck<br />
GSK<br />
Aventis
Change language